Investigational OCTA Devices Show Promise in Diabetic Disease Assessment - Summary - MDSpire

Investigational OCTA Devices Show Promise in Diabetic Disease Assessment

At Retina World Congress, Patricio G. Schlottmann, MD, discussed investigational widefield OCTA platforms made by Chinese company TowardPi Medical.

  • By

  • Patricio G. Schlottmann, MD

  • Patricio G. Schlottmann, MD

  • May 14, 2026

  • 2 min

Share

Objective:

To evaluate the effectiveness of ultrawidefield optical coherence tomography angiography (OCTA) in assessing diabetic retinal disease.

Key Findings:
  • OCTA is a good predictor of disease progression in diabetic retinopathy and macular edema.
  • The devices allow for imaging without pupil dilation.
  • Ultrawidefield OCTA captures 24-mm images in one go.
Interpretation:

The investigational OCTA devices show promise for non-invasive assessment and management of diabetic eye disease.

Limitations:
  • Devices are not yet licensed in the United States.
  • Data is based on investigational use and may require further validation.
Conclusion:

Ultrawidefield OCTA may significantly improve the detection and management of diabetic retinal disease.

Original Source(s)

Investigational OCTA Devices Show Promise in Diabetic Disease Assessment

  • by Patricio G. Schlottmann, MD, Patricio G. Schlottmann, MD

  • May 14, 2026

Related Content

Semaglutide Linked to NAION Risk

A retrospective database study found a low absolute incidence but higher relative hazard of ischemic optic neuropathy following semaglutide initiation.

Lipid-Derived Biomarkers for NAION

TVST study reveals potential new metabolic signal in nonarteritic anterior ischemic optic neuropathy

  • March 13, 2026

  • 4 min
Steroid Strategies in Diabetic Macular Edema